IL146575A0 - Compositions of a-beta peptide and processes for producing same - Google Patents
Compositions of a-beta peptide and processes for producing sameInfo
- Publication number
- IL146575A0 IL146575A0 IL14657500A IL14657500A IL146575A0 IL 146575 A0 IL146575 A0 IL 146575A0 IL 14657500 A IL14657500 A IL 14657500A IL 14657500 A IL14657500 A IL 14657500A IL 146575 A0 IL146575 A0 IL 146575A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- processes
- producing same
- beta peptide
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13704799P | 1999-06-01 | 1999-06-01 | |
| PCT/US2000/015302 WO2000072870A1 (en) | 1999-06-01 | 2000-06-01 | Compositions of a-beta peptide and processes for producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL146575A0 true IL146575A0 (en) | 2002-07-25 |
Family
ID=22475602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14657500A IL146575A0 (en) | 1999-06-01 | 2000-06-01 | Compositions of a-beta peptide and processes for producing same |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1181040A1 (en) |
| JP (1) | JP2003519620A (en) |
| KR (1) | KR20020016813A (en) |
| CN (1) | CN1353615A (en) |
| AR (1) | AR024558A1 (en) |
| AU (1) | AU5726100A (en) |
| BG (1) | BG106249A (en) |
| BR (1) | BR0011251A (en) |
| CA (1) | CA2374897A1 (en) |
| CZ (1) | CZ20014150A3 (en) |
| EE (1) | EE200100649A (en) |
| HK (1) | HK1045938A1 (en) |
| HR (1) | HRP20010901A2 (en) |
| IL (1) | IL146575A0 (en) |
| IS (1) | IS6182A (en) |
| MX (1) | MXPA01012355A (en) |
| NO (1) | NO20015859L (en) |
| NZ (1) | NZ515744A (en) |
| PE (1) | PE20010212A1 (en) |
| PL (1) | PL352575A1 (en) |
| RU (1) | RU2001135800A (en) |
| SK (1) | SK17012001A3 (en) |
| TR (1) | TR200103476T2 (en) |
| WO (1) | WO2000072870A1 (en) |
| ZA (1) | ZA200109704B (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| WO2002025279A2 (en) * | 2000-09-19 | 2002-03-28 | Evotec Neurosciences Gmbh | Use of amyloid precursor protein for treating brain amyloidosis |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
| PL2289909T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| NZ567888A (en) | 2006-03-23 | 2010-08-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| JP5889529B2 (en) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Treatment of amyloidogenic diseases |
| JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| CN112390881A (en) | 2014-07-10 | 2021-02-23 | 生命北极神经科学公司 | Improved a β protofibril binding antibodies |
| CN114306629B (en) | 2016-01-08 | 2023-11-10 | 阿森迪斯药物生长障碍股份有限公司 | Controlled release CNP agonists with increased NEP stability |
| CN114957438B (en) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | Human Abeta 1-42 epitope polypeptide for detecting Alzheimer disease and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69126304T2 (en) * | 1990-04-27 | 1997-09-04 | Mcmichael, John, Delanson, N.Y. | METHOD AND COMPOSITION FOR TREATING DISEASES OF THE CNS CAUSED BY ABNORMAL BETA AMYLOID PROTEIN |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/en not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/en unknown
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/en unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 EE EEP200100649A patent/EE200100649A/en unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/en unknown
- 2000-06-01 PL PL00352575A patent/PL352575A1/en not_active Application Discontinuation
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/en not_active Withdrawn
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/en unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/en unknown
- 2000-06-01 IL IL14657500A patent/IL146575A0/en unknown
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/en not_active Application Discontinuation
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/en unknown
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 CN CN00808374A patent/CN1353615A/en active Pending
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/en not_active Application Discontinuation
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/en unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/en not_active Application Discontinuation
- 2001-12-04 HR HR20010901A patent/HRP20010901A2/en not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/en unknown
-
2002
- 2002-08-23 HK HK02106241.2A patent/HK1045938A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20015859L (en) | 2002-02-01 |
| SK17012001A3 (en) | 2002-06-04 |
| BG106249A (en) | 2002-08-30 |
| CN1353615A (en) | 2002-06-12 |
| NZ515744A (en) | 2004-04-30 |
| CZ20014150A3 (en) | 2002-05-15 |
| WO2000072870A1 (en) | 2000-12-07 |
| PL352575A1 (en) | 2003-08-25 |
| AR024558A1 (en) | 2002-10-16 |
| JP2003519620A (en) | 2003-06-24 |
| EE200100649A (en) | 2003-02-17 |
| KR20020016813A (en) | 2002-03-06 |
| RU2001135800A (en) | 2003-08-20 |
| MXPA01012355A (en) | 2003-06-24 |
| NO20015859D0 (en) | 2001-11-30 |
| CA2374897A1 (en) | 2000-12-07 |
| IS6182A (en) | 2001-11-29 |
| HRP20010901A2 (en) | 2003-04-30 |
| EP1181040A1 (en) | 2002-02-27 |
| ZA200109704B (en) | 2003-02-26 |
| BR0011251A (en) | 2002-03-05 |
| TR200103476T2 (en) | 2002-04-22 |
| PE20010212A1 (en) | 2001-02-22 |
| AU5726100A (en) | 2000-12-18 |
| HK1045938A1 (en) | 2002-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL352575A1 (en) | Compositions of a-beta peptide and processes for producing same | |
| AU4133701A (en) | Methods and compositions for peptide synthesis | |
| AP2002002515A0 (en) | Composition for ipregnation of fabrics and nettings | |
| AU2002233929A1 (en) | Compositions of peptide crystals | |
| HUP0101580A3 (en) | Pharmaceutical compositions capable of being gelled | |
| IL140214A0 (en) | Butterlike compositions and methods of manufacturing same | |
| AU6041499A (en) | Rheology modified compositions and processes thereof | |
| GB9924351D0 (en) | Immunomodulation methods and compositions | |
| EP1180006A4 (en) | Compositions and methods for their preparation from lepidium | |
| HUP0101243A3 (en) | Novel compositions of eprosartan | |
| HUP0202729A3 (en) | Compositions for parenteral use of estramustine phosphate and amino acids | |
| GB0126643D0 (en) | Composition and process | |
| HUP9904332A3 (en) | Compositions and articles of manufacture | |
| GB9926671D0 (en) | Sealing of relatively movable parts | |
| PL337804A1 (en) | Solubilised compositions of sertralin | |
| EP1163340A4 (en) | Compositions and methods for the modification of gene expression | |
| ZA200004376B (en) | Process for the preparation of tetrapeptide | |
| ZA988450B (en) | Process for improving the plasticity of ceramic compositions and for reversing this effect | |
| EP1096927A4 (en) | Composition for treatment of stress | |
| GB2338234B (en) | Preparation of finasteride | |
| EP1033999A4 (en) | Compositions of leukaemia inhibitory factor | |
| HUP0201410A3 (en) | Compositions of a-betha peptide and processes for producing same | |
| HK1037139A1 (en) | Novel uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same | |
| IL121719A (en) | Deicing composition and process of production thereof | |
| IL154785A0 (en) | Polymorphic form of finasteride and processes for the preparation thereof |